We present a report regarding the cytotoxic effects of iron-based magnetic nanoparticles conjugated with fluorodeoxyglucose (FDG-mNPs) on the viability of NCI-H727 and SH-SY5Y cancer cells. MTT assays were performed to determine cell viability in treated cancer cells grown under standard 2D culture conditions. FDG-mNP concentrations of 0.075 mg/mL, 0.15 mg/mL, and 0.3 mg/mL decreased mean cell viability of NCI-H727 cells to 92.5%, 82.9%, and 75% respectively. FDG-mNPs was also shown to have a detrimental effect on the viability of SY5Y cells: a decrease of 5.7%, 18.6%, and 36.4% was found for SY5Y cells treated with 0.075 mg/mL, 0.15 mg/mL, and 0.3 mg/mL concentrations of FDG-mNPs, respectively. When NCI-H727 and SH-SY5Y cancer cells were grown as 3D spheroids, morphology was visibly changed and the number of viable cells was decerased in spheroids treated with FDG-mNPs compared with untreated spheroids. The results of our study demonstrated that FDG-mNP has toxic effects on NCI-H7272 and SY5Y cancer cells, and we conclude that conjugated FDG-mNPs are promising in the development of clinical applications for the destruction of cancer cells.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792519PMC
http://dx.doi.org/10.26655/AJNANOMAT.2021.1.5DOI Listing

Publication Analysis

Top Keywords

cancer cells
24
nci-h727 sh-sy5y
12
sh-sy5y cancer
12
cells
10
magnetic nanoparticles
8
viability nci-h727
8
cell viability
8
cells grown
8
0075 mg/ml
8
mg/ml 015
8

Similar Publications

Cisplatin, a platinum-based chemotherapeutic agent, can be used to treat cervical cancer (CC), but cisplatin resistance is increased during the cisplatin treatment. Long non-coding RNA PGM5-AS1 reportedly participates in CC tumorigenesis; however, its role in CC patients with cisplatin resistance has not been revealed. The present aimed to examine the role of PGM5-AS1 in modulating cisplatin resistance in CC.

View Article and Find Full Text PDF

Germline inactivating mutations of the SLC25A1 gene contribute to various human disorders, including Velocardiofacial (VCFS), DiGeorge (DGS) syndromes and combined D/L-2-hydroxyglutaric aciduria (D/L-2HGA), a severe systemic disease characterized by the accumulation of 2-hydroxyglutaric acid (2HG). The mechanisms by which SLC25A1 loss leads to these syndromes remain largely unclear. Here, we describe a mouse model of SLC25A1 deficiency that mimics human VCFS/DGS and D/L-2HGA.

View Article and Find Full Text PDF

The emergence of self-propelling magnetic nanobots represents a significant advancement in the field of drug delivery. These magneto-nanobots offer precise control over drug targeting and possess the capability to navigate deep into tumor tissues, thereby addressing multiple challenges associated with conventional cancer therapies. Here, Fe-GSH-Protein-Dox, a novel self-propelling magnetic nanobot conjugated with a biocompatible protein surface and loaded with doxorubicin for the treatment of triple-negative breast cancer (TNBC), is reported.

View Article and Find Full Text PDF

Optimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC.

Sci Rep

December 2024

Interventional Oncology, Johnson & Johnson Enterprise Innovation, Inc, 10th Floor 255 Main St, 02142, Cambridge, Boston, MA, USA.

The introduction of anti-PD-1/PD-L1 therapies revolutionized treatment for advanced non-small cell lung cancer (NSCLC), yet response rates remain modest, underscoring the need for predictive biomarkers. While a T cell inflamed gene expression profile (GEP) has predicted anti-PD-1 response in various cancers, it failed in a large NSCLC cohort from the Stand Up To Cancer-Mark (SU2C-MARK) Foundation. Re-analysis revealed that while the T cell inflamed GEP alone was not predictive, its performance improved significantly when combined with gene signatures of myeloid cell markers.

View Article and Find Full Text PDF

LAG3 plays a regulatory role in immunity and emerged as an inhibitory immune checkpoint molecule comparable to PD-L1 and CTLA-4 and a potential target for enhancing anti-cancer immune responses. We generated 3D cancer cultures as a model to identify novel molecular biomarkers for the selection of patients suitable for α-LAG3 treatment and simultaneously the possibility to perform an early diagnosis due to its higher presence in breast cancer, also to achieve a theragnostic approach. Our data confirm the extreme dysregulation of LAG3 in breast cancer with significantly higher expression in tumor tissue specimens, compared to non-cancerous tissue controls.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!